https://www.neurologylive.com/view/lighthouse-study-initiated-trend-toward-asms-lower-teratogenic-risk-rituximab-effects-nmosd-mogad
0
0
Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD - Neurology Live
+ 63 more
10/15/22 at 11:00am
Organization
Neurologylive.com
Author
NeurologyLive® Staff
Details
33 words
Summarize
Health LIGHTHOUSE Study Rituximab Effects NMOSD Lower Teratogenic Risk MOGAD - Neurology Live Neurology News Network
Neurology News Network for the week ending October 15, 2022. [WATCH TIME: 3 minutes]
Create an account or login to join the discussion